September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Modulation of P75NTR receptor protects against ischemic retinopathy: possible contribution of mesenchymal stem cells (MSCs)
Author Affiliations & Notes
  • Sally Elshaer
    Clinical and Experimental Therapeutics, University of Georgia, Augusta, Georgia, United States
  • Azza B. El-Remessy
    Clinical and Experimental Therapeutics, University of Georgia, Augusta, Georgia, United States
  • William Dave Hill
    Georgia Regents University, Augusta, Georgia, United States
  • Footnotes
    Commercial Relationships   Sally Elshaer, None; Azza El-Remessy, None; William Dave Hill, None
  • Footnotes
    Support  AHA-15PRE22830019
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 2707. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Sally Elshaer, Azza B. El-Remessy, William Dave Hill; Modulation of P75NTR receptor protects against ischemic retinopathy: possible contribution of mesenchymal stem cells (MSCs). Invest. Ophthalmol. Vis. Sci. 2016;57(12):2707.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Proliferative diabetic retinopathy (PDR) is characterized by accelerated cell death, impaired vascular repair and pathological retinal neovascularization (RNV). Mesenchymal stem cells (MSCs) are promising therapy to improve vascular repair, yet their role in PDR is not fully understood. We have shown that genetic deletion of neurotrophin receptor; p75NTR enhanced vascular repair and ameliorated RNV in ischemic retinopathy model. Furthermore, its deletion preserved the expression of angiogenic markers; SDF-1, CXCR-4 and CXCR-7 responsible for MSCs homing to vasculature in diabetic ischemic limbs. The aim of this study is to investigate the contribution of MSCs to vascular protection associated with p75NTR deletion in ischemic retina.

Methods : WT and p75KO mice were subjected to ischemia reperfusion (IR) injury by increasing intra-ocular pressure to 120 mmHg for 45 minutes followed by perfusion. Murine GFP-labeled MSCs (100,000 cells/eye) were injected intravitreally 2 days post-surgery and vascular homing was assessed 1-week later. Acellular capillaries were counted using trypsin digest 10-days post IR. In vitro, MSCs were treated with a specific pharmacological inhibitor against p75NTR receptor (LM11A-31, 200 nM, Stanford University) and conditioned media was co-cultured with human retinal endothelial (HREs) to examine the angiogenic response.

Results : IR increased number of acellular capillaries (~ 2.3 fold) in WT mice, but not in p75KO compared to sham-controls. GFP-MSCs showed better incorporation into retinal vasculature in p75KO mice compared to WT. Administration of MSCs decreased number of acellular capillaries in all groups (~ 2.3 fold decrease in WT-sham, 2.7 fold decrease in WT-IR, 3 fold decrease in KO-Sham and 2.5 fold decrease in KO-IR). In vitro, inhibition p75NTR in MSCs enhanced the angiogenic response of their conditional media in HREs, where HREs showed enhanced migration (~ 1.3 fold) and tube formation (~ 2.7 fold) compared to controls.

Conclusions : Our results showed that deletion of p75NTR protects against retinal ischemia by mechanisms that partially involve improved MSCs homing to ischemic vasculature to prevent vascular degeneration and support newly grown blood vessels. Thus, combination of MSCs injection and p75NTR inhibitor can serve as potential therapeutic strategy to harness vascular repair in ischemic retinopathy diseases.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×